Antibody Therapies are here to Revolutionize Dermatology

02/11/2016 - 2 minutes

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership!  

LogosMorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos and Boehringer Ingelheim. Now, the company is teaming up with Leo Pharma, a Danish company focusing on dermatology therapies. The aim: to discover and develop antibody-based treatments for skin diseases.

MorphoSys will take care of the preclinical stage using its Ylanthia antibody library to match drug candidates to targets provided by Leo Pharma, which will be responsible for clinical development and commercialization. However, MorphoSys will be able to take part in these steps in the case of any cancer programs that arise from the collaboration. Leo Pharma will pay for R&D, as well as milestones and royalties of up to a sweet €111.5M per antibody program.

Dermatology is an area with little innovation despite the big unmet clinical need.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member